Literature DB >> 1374041

Metabolic activity in inflammatory and non-inflammatory aneurysms of the abdominal aorta.

W G Tennant1, R N Baird, M Horrocks.   

Abstract

Inflammatory aneurysms of the abdominal aorta (IAA) comprise 10-15% of all aortic aneurysms (AA) but their aetiology and pathogenesis are obscure. Destruction of mural elastin is a prominent feature of IAA, and both increased elastolysis and decreased inhibition of elastolysis have been implicated. In order to study these factors, we have examined the peripheral blood of three groups of patients; 15 with inflammatory aortic aneurysms (IAA), 61 with simple aortic aneurysms (SAA) and 35 with aorto-iliac occlusive disease (OD). In all cases, alpha-1-anti-trypsin (A-1-AT), alpha-2-macroglobulin (A-2-MG), elastase inhibitory activity (E.I.A.), elastase-anti-trypsin complex, C-reactive protein (CRP), caeruloplasmin (CP) and plasma viscosity were measured. Patients with IAA had a significantly higher plasma viscosity (Mann-Whitney, p less than 0.05), E.I.A. (Mann-Whitney, p less than 0.01) and levels of A-1-AT, CRP, CP and elastase/anti-trypsin complex (Mann-Whitney, all p less than 0.05) than patients in the other two groups. There was no difference in the levels of A-2-MG between any of the groups. This study refutes the theory that reduced inhibition of elastase activity predisposes to the formation of SAA. In patients with IAA, raised marker levels indicate ongoing destruction of elastin, and suggest a difference in pathogenesis between IAA and SAA. The study also suggests that IAA are highly active metabolically, as opposed to the more degenerative SAA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1374041     DOI: 10.1016/s0950-821x(05)80241-5

Source DB:  PubMed          Journal:  Eur J Vasc Surg        ISSN: 0950-821X


  1 in total

1.  Regression of inflammatory abdominal aortic aneurysm after endoluminal treatment with bare-metal Wallstent endoprostheses.

Authors:  R P Villareal; M H Howell; Z Krajcer
Journal:  Tex Heart Inst J       Date:  2000
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.